Abstract
Quantitative structure-activity relationship studies on a series of selective inhibitors of thrombin and factor Xa were performed by using Associative Neural Network. To overcome the problem of overfitting due to descriptor selection, 5-fold cross-validation with variable selection in each step of the analysis was performed. The predictive ability of the models was tested through leave-one-out cross-validation, giving a Q2=0.74 - 0.87 for regression models. Predictions for the external evaluation sets obtained accuracies in the range of 0.71 - 0.82 for regressions. The proposed models can be potential tools for finding new drug candidates.
Keywords: Drug design, factor Xa, QSAR, Neural Networks, thrombin.
Current Computer-Aided Drug Design
Title:Prediction of Thrombin and Factor Xa Inhibitory Activity with Associative Neural Networks
Volume: 10 Issue: 3
Author(s): Vasyl Kovalishyn, Vsevolod Tanchuk, Iryna Kopernyk, Volodymyr Prokopenko and Larysa Metelytsia
Affiliation:
Keywords: Drug design, factor Xa, QSAR, Neural Networks, thrombin.
Abstract: Quantitative structure-activity relationship studies on a series of selective inhibitors of thrombin and factor Xa were performed by using Associative Neural Network. To overcome the problem of overfitting due to descriptor selection, 5-fold cross-validation with variable selection in each step of the analysis was performed. The predictive ability of the models was tested through leave-one-out cross-validation, giving a Q2=0.74 - 0.87 for regression models. Predictions for the external evaluation sets obtained accuracies in the range of 0.71 - 0.82 for regressions. The proposed models can be potential tools for finding new drug candidates.
Export Options
About this article
Cite this article as:
Kovalishyn Vasyl, Tanchuk Vsevolod, Kopernyk Iryna, Prokopenko Volodymyr and Metelytsia Larysa, Prediction of Thrombin and Factor Xa Inhibitory Activity with Associative Neural Networks, Current Computer-Aided Drug Design 2014; 10 (3) . https://dx.doi.org/10.2174/157340991003150302231419
DOI https://dx.doi.org/10.2174/157340991003150302231419 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Recent Developments in Bioactive Ceramic/Glass: Preparation and Application in Tissue Engineering and Drug Delivery
Recent Patents on Materials Science Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs)
Recent Patents on Cardiovascular Drug Discovery Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Plasma Substitutes Therapy in Pediatrics
Current Drug Targets Platelets and Atherothrombosis: Causes, Targets and Treatments for Thrombosis
Current Medicinal Chemistry Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Antileukotriene Treatment in Children with Asthma - New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Nitrogen Containing Privileged Structures and their Solid Phase Combinatorial Synthesis
Combinatorial Chemistry & High Throughput Screening Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Current Drug Targets